Ixazomib citrate is primarily used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It is often prescribed for patients who have received at least one prior therapy. As a proteasome inhibitor, it works by blocking the action of proteasomes, which are cellular complexes that break down proteins. By inhibiting proteasomes, it leads to the accumulation of damaged proteins in cancer cells, ultimately causing their death. It is typically administered orally, making it a convenient option for patients compared to intravenous treatments. Ixazomib citrate is commonly used in combination with other medications, such as lenalidomide and dexamethasone, to enhance its effectiveness. Its use has shown to improve progression-free survival and overall response rates in patients with relapsed or refractory multiple myeloma. Regular monitoring is required to manage potential side effects, such as thrombocytopenia, gastrointestinal issues, and peripheral neuropathy.